Aging-related changes in the nigrostriatal dopamine system and the response to MPTP in nonhuman primates: Diminished compensatory mechanisms as a prelude to parkinsonism

Neurobiology of Disease

Volumn 26, Issue 1, 2007, Pages 56-65

  Collier, Timothy J ^a   Lipton, Jack ^a   Daley, Brian F ^a   Palfi, Stephane ^b   Chu, Yaping ^c   Sortwell, Caryl ^a   Bakay, Roy A E ^c   Sladek Jr , John R ^d   Kordower, Jeffrey H ^c  

^a UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^b DIF   (France)

^c RUSH UNIVERSITY MEDICAL CENTER   (United States)

^d UNIVERSITY OF COLORADO   (United States)

Author keywords

Aging; Dopamine; Monkey; MPTP; Parkinsonism; Substantia nigra

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; DOPAMINE; HOMOVANILLIC ACID; TYROSINE 3 MONOOXYGENASE;

ADOLESCENT; AGE; AGED; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CORPUS STRIATUM; DOPAMINERGIC SYSTEM; FEMALE; NERVE CELL PLASTICITY; NONHUMAN; OPTICAL DENSITY; PARKINSONISM; PRIORITY JOURNAL; RHESUS MONKEY; RISK FACTOR;

AGING; ANIMALS; BEHAVIOR, ANIMAL; BRAIN; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DOPAMINE; FEMALE; IMMUNOHISTOCHEMISTRY; MACACA MULATTA; MOTOR ACTIVITY; MPTP POISONING; NEOSTRIATUM; PARKINSON DISEASE, SECONDARY; SUBSTANTIA NIGRA; TYROSINE 3-MONOOXYGENASE;

EID: 33947211176     PISSN: 09699961     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.nbd.2006.11.013     Document Type: Article

References (33)

1. Andersen A.H., Zhang Z., Zhang M., Gash D.M., and Avison M.J. Age-associated changes in rhesus CNS composition identified by MRI. Brain Res. 829 (1999) 90-98
2. Bankiewicz K.S., Oldfield E.H., Chiueh C.C., Doppman J.L., Jacobowitz D.M., and Kopin I.J. Hemiparkinsonism in monkeys after unilateral internal carotid artery infusion of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). Life Sci. 39 (1986) 7-16
3. Calne D.B., and Langston J.W. Aetiology of Parkinson's disease. Lancet 2 (1983) 1457-1459
4. Carvey P.M., Punati A., and Newman M.B. Progressive dopamine neuron loss in Parkinson's disease: the multiple hit hypothesis. Cell Transplant 15 (2006) 239-250
5. Collier T.J., Ling Z.D., Carvey P.M., Fletcher-Turner A., Yurek D.M., Sladek Jr. J.R., and Kordower J.H. Striatal trophic factor activity in aging monkeys with unilateral MPTP-induced parkinsonism. Exp. Neurol. 191 (2005) S60-S67
6. Damier P., Hirsch E.C., Agid Y., and Graybiel A.M. The substantia nigra of the human brain: II. Patterns of loss of dopamine-containing neurons in Parkinson's disease. Brain 122 Pt 8 (1999) 1437-1448
7. Emborg M.E., Ma S.Y., Mufson E.J., Levey A.I., Taylor M.D., Brown W.D., Holden J.E., and Kordower J.H. Age-related declines in nigral neuronal function correlate with motor impairments in rhesus monkeys. J. Comp. Neurol. 401 (1998) 253-265
8. Emborg M.E., Shin P., Roitberg B., Sramek J.G., Chuy Y., Stebbins G.T., Hamilton J.S., Suzdak P.D., Steiner J.P., and Kordower J.H. Systemic administration of the immunophilin ligand GPI 1046 in MPTP-treated monkeys. Exp. Neurol. 168 (2001) 171-182
9. Fahn S. Description of Parkinson's disease as a clinical syndrome. In: Federoff H.J., Burke R.E., Fahn S., and Fiskum G. (Eds). Parkinson's Disease. The Life Cycle of the Dopamine Neuron. Annals of the New York Academy of Sciences, New York vol. 991 (2003) 1-14
10. Fearnley J.M., and Lees A.J. Aging and Parkinson's disease substantia nigra regional selectivity. Brain 114 (1991) 2283-2301
11. Gerhardt G.A., Cass W.A., Yi A., Zhang Z., and Gash D.M. Changes in somatodendritic but not terminal dopamine regulation in aged rhesus monkeys. J. Neurochem. 80 (2002) 168-177
12. German D.C., Manaye K., Smith W.K., Woodward D.J., and Saper C.B. Midbrain dopaminergic cell loss in Parkinson's disease: computer visualization. Ann. Neurol. 26 (1989) 507-514
13. Goldman-Rakic P.S., and Brown R.M. Regional changes of monoamines in cerebral cortex and subcortical structures of aging rhesus monkeys. Neuroscience 6 (1981) 177-187
14. Guttman M., Fibiger H.C., Jakubovic A., and Calne D.B. Intracarotid 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine administration: biochemical and behavioral observations in a primate model of hemiparkinsonism. J. Neurochem. 54 (1990) 1329-1334
15. Irwin I., DeLanney L.E., McNeill T., Chan P., Forno L.S., Murphy Jr. G.M., Di Monte D.A., Sandy M.S., and Langston J.W. Aging and the nigrostriatal dopamine system: a non-human primate study. Neurodegen 3 (1994) 251-265
16. Kanaan N.M., Kordower J.H., and Collier T.J. Accumulation of intracellular inclusions in dopaminergic subregions of the midbrain during normal aging in the rhesus monkey: relevance in differential susceptibility to degeneration. Abstr.-Soc. Neurosci. (2006) 751.1
17. Kish S.J., Shannak K., Rajput A., Deck J.H.N., and Hornykiewicz O. Aging produces a specific pattern of striatal dopamine loss: implications for the etiology of idiopathic Parkinson's disease. J. Neurochem. 58 (1992) 642-648
18. Kubis N., Faucheux B.A., Ransmayr G., et al. Preservation of midbrain catecholaminergic neurons in very old human subjects. Brain 123 (2000) 366-373
19. Ling Z., Zhu Y., Tong C.W., Snyder J.A., Lipton J.W., and Carvey P.M. Progressive dopamine neuron loss following supra-nigral lipopolysaccharide (LPS) infusion into rats exposed to LPS prenatally. Exp. Neurol. 199 (2006) 499-512
20. Mayeux R., Marder K., Cote L.J., Denaro J., Hemenegildo N., Mejia H., Tang M.X., Lantigua R., Wilder D., Gurland B., et al. The frequency of idiopathic Parkinson's disease by age, ethnic group, and sex in northern Manhattan, 1988-1993. Am. J. Epidemiol. 142 (1995) 820-827
21. McCormack A.L., Di Monte D.A., Delfani K., Irwin I., DeLanney L.E., Langston W.J., and Janson A.M. Aging of the nigrostriatal system in the squirrel monkey. J. Comp. Neurol. 471 (2004) 387-395
22. Morgan D.G., and Finch C.E. Dopaminergic changes in the basal ganglia. A generalized phenomenon of aging in mammals. In: Joseph J.A. (Ed). Central Determinants of Age-related Declines in Motor Function. Annals of the New York Academy of Sciences, New York vol. 515 (1988) 145-160
23. Oiwa Y., Eberling J.L., Nagy D., Pivirotto P., Emborg M.E., and Bankiewicz K.S. Overlesioned hemiparkinsonian non human primate model: correlation between clinical, neurochemical and histochemical changes. Front. Biosci. 8 (2003) a155-a166
24. Ovadia A., Zhang Z., and Gash D.M. Increased susceptibility to MPTP toxicity in middle-aged rhesus monkeys. Neurobiol. Aging 16 (1995) 931-937
25. Pakkenberg H., Andersen B.B., Burns R.S., and Pakkenberg B. A stereological study of substantia nigra in young and old rhesus monkeys. Brain Res. 693 (1995) 201-206
26. Palomobo E., Porrino L.F., Bankiewicz K.S., Crane A.M., Sokoloff L., and Kopin I.J. Local cerebral glucose utilization in monkeys with hemiparkinsonism induced by intracarotid infusion of the neurotoxin MPTP. J. Neurosci. 10 (1990) 860-869
27. Pate B.D., Kawamata T., Yamada T., McGeer E.G., Hewitt K.A., Snow B.J., Ruth T.J., and Calne D.B. Correlation of striatal fluorodopa uptake in the MPTP monkey with dopaminergic indices. Ann. Neurol. 34 (1993) 331-338
28. Sladek Jr. J.R., Elsworth J., Taylor J.R., Roth R.H., and Redmond Jr. D.E. Techniques for neural transplantation in non-human primates. Methods in Cell Transplantation (1995), RB Landes, Austin, TX 391-408
29. Tanner C.M., and Goldman S.M. Epidemiology of Parkinson's disease. Neurol. Clin. 14 (1996) 317-335
30. Thiruchelvam M., McCormack A., Richfield E.K., Baggs R.B., and Cory-Slechta D.A. Age-related irreversible progressive nigrostriatal dopaminergic neurotoxicity in the paraquat and maneb model of Parkinson's disease. Eur. J. Neurosci. 18 (2003) 589-600
31. Thiruchelvam M., Powers J.M., Cory-Slechta D.A., and Richfield E.K. Risk factors for dopaminergic neuron loss in human alpha-synuclein transgenic mice. Eur. J. Neurosci. 19 (2004) 845-854
32. Totaro R., Marini C., Pistoia F., Sacco S., Russo T., and Carolei A. Prevalence of Parkinson's disease in the L'Aquila district, central Italy. Acta Neurol. Scand. 112 (2005) 24-28
33. Zigmond M.J., Abercrombie E.D., Berger T.W., Grace A.A., and Stricker E.M. Compensations after lesions of central dopaminergic neurons: some clinical and basic implications. Trends Neurosci. 13 (1990) 290-296